Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 9/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994086 | 0.92 | HRH3 (0.47) | MCHR1CHRM1HRH3NPC1DRD4 | |
| SCHEMBL3006201 | 0.79 | HPGD (0.41) | RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL13213000 | 0.77 | MCHR1 (0.61) | MCHR1HTR2ACHRM1RAB9AMEN1 | |
| SCHEMBL3003570 | 0.77 | MCHR1 (0.66) | MCHR1HTR2ACHRM1HRH3RAB9A | |
| SCHEMBL2996636 | 0.76 | MCHR1 (0.52) | MCHR1HTR2ACHRM1HRH3RAB9A | |
| SCHEMBL3006769 | 0.74 | MCHR1 (0.61) | MCHR1HTR2ACHRM1RAB9AMEN1 | |
| SCHEMBL13212996 | 0.74 | MCHR1 (0.54) | MCHR1HTR2ACHRM1HRH3RAB9A | |
| SCHEMBL13212992 | 0.73 | MCHR1 (0.63) | MCHR1HTR2ACHRM1RAB9ANPC1 | |
| Trifluoroacetic Acid SCHEMBL3005955 | 0.73 | MCHR1 (0.58) | MCHR1HTR2ACHRM1RAB9AACHE | |
| SCHEMBL23530302 | 0.73 | POLB (0.41) | RAB9AMEN1ALDH1A1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| EP-2102171-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071646-A1 | NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | MCHR1 1/4885HTR2A 71/4885CHRM1 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.